Clinical Trial: A Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06952478) titled 'A Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma' on April 29.

Brief Summary: This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma

Study Start Date: May 31

Study Type: INTERVENTIONAL

Condition: Refractory or Relapsed Multiple Myeloma

Intervention: BIOLOGICAL: CT-P44(Daratumumab)

CT-P44 ...